Vaxart, Inc. (VXRT)
USD 0.45
(4.92%)
USD 0.45
(4.92%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 91.83 Million USD | -40.31% |
| 2022 | 153.84 Million USD | -30.44% |
| 2021 | 221.16 Million USD | 44.95% |
| 2020 | 152.58 Million USD | 312.03% |
| 2019 | 37.03 Million USD | 5.12% |
| 2018 | 35.22 Million USD | 678.84% |
| 2017 | 4.52 Million USD | -88.72% |
| 2016 | 40.1 Million USD | -44.84% |
| 2015 | 72.7 Million USD | -8.44% |
| 2014 | 79.4 Million USD | -30.35% |
| 2013 | 114 Million USD | 32.87% |
| 2012 | 85.8 Million USD | -12.42% |
| 2011 | 97.96 Million USD | -13.97% |
| 2010 | 113.87 Million USD | -13.29% |
| 2009 | 131.31 Million USD | -8.95% |
| 2008 | 144.22 Million USD | -39.55% |
| 2007 | 238.57 Million USD | -10.27% |
| 2006 | 265.87 Million USD | -19.27% |
| 2005 | 329.33 Million USD | -10.55% |
| 2004 | 368.17 Million USD | -4.94% |
| 2003 | 387.3 Million USD | 66.35% |
| 2002 | 232.81 Million USD | -24.97% |
| 2001 | 310.3 Million USD | 38.23% |
| 2000 | 224.48 Million USD | 4.61% |
| 1999 | 214.6 Million USD | -1.69% |
| 1998 | 218.3 Million USD | -3.36% |
| 1997 | 225.9 Million USD | 11.78% |
| 1996 | 202.1 Million USD | 46.45% |
| 1995 | 138 Million USD | 47.12% |
| 1994 | 93.8 Million USD | 77.32% |
| 1993 | 52.9 Million USD | 11.37% |
| 1992 | 47.5 Million USD | 78.57% |
| 1991 | 26.6 Million USD | 12.24% |
| 1990 | 23.7 Million USD | -2.87% |
| 1989 | 24.4 Million USD | 16.75% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 113.74 Million USD | 28.28% |
| 2024 Q1 | 88.67 Million USD | -3.44% |
| 2023 Q1 | 129.85 Million USD | -15.6% |
| 2023 Q2 | 122.65 Million USD | -5.54% |
| 2023 Q3 | 105.64 Million USD | -13.87% |
| 2023 Q4 | 91.83 Million USD | -13.07% |
| 2023 FY | 91.83 Million USD | -40.31% |
| 2022 Q3 | 175.3 Million USD | -3.39% |
| 2022 Q4 | 153.84 Million USD | -12.24% |
| 2022 Q1 | 200.37 Million USD | -9.4% |
| 2022 FY | 153.84 Million USD | -30.44% |
| 2022 Q2 | 181.45 Million USD | -9.44% |
| 2021 Q4 | 221.16 Million USD | -8.28% |
| 2021 FY | 221.16 Million USD | 44.95% |
| 2021 Q2 | 228.84 Million USD | 11.16% |
| 2021 Q1 | 205.86 Million USD | 34.92% |
| 2021 Q3 | 241.13 Million USD | 5.37% |
| 2020 FY | 152.58 Million USD | 312.03% |
| 2020 Q3 | 154.71 Million USD | 141.02% |
| 2020 Q2 | 64.19 Million USD | 22.12% |
| 2020 Q4 | 152.58 Million USD | -1.38% |
| 2020 Q1 | 52.56 Million USD | 41.94% |
| 2019 FY | 37.03 Million USD | 5.12% |
| 2019 Q1 | 36.3 Million USD | 3.07% |
| 2019 Q2 | 37.25 Million USD | 2.59% |
| 2019 Q4 | 37.03 Million USD | -13.26% |
| 2019 Q3 | 42.69 Million USD | 14.62% |
| 2018 Q3 | 40.63 Million USD | -14.91% |
| 2018 Q1 | 56.53 Million USD | 73.43% |
| 2018 FY | 35.22 Million USD | 678.84% |
| 2018 Q4 | 35.22 Million USD | -13.31% |
| 2018 Q2 | 47.75 Million USD | -15.53% |
| 2017 Q1 | 46.7 Million USD | -17.35% |
| 2017 Q4 | 32.6 Million USD | -6.05% |
| 2017 FY | 4.52 Million USD | -88.72% |
| 2017 Q3 | 34.7 Million USD | -13.47% |
| 2017 Q2 | 40.1 Million USD | -14.13% |
| 2016 Q2 | 72.7 Million USD | 17.45% |
| 2016 FY | 40.1 Million USD | -44.84% |
| 2016 Q3 | 63.1 Million USD | -13.2% |
| 2016 Q1 | 61.9 Million USD | -3.58% |
| 2016 Q4 | 56.5 Million USD | -10.46% |
| 2015 FY | 72.7 Million USD | -8.44% |
| 2015 Q4 | 64.2 Million USD | -9.58% |
| 2015 Q3 | 71 Million USD | -10.58% |
| 2015 Q2 | 79.4 Million USD | -10.59% |
| 2015 Q1 | 88.8 Million USD | -4.93% |
| 2014 Q1 | 120.5 Million USD | 45.71% |
| 2014 Q2 | 114 Million USD | -5.39% |
| 2014 FY | 79.4 Million USD | -30.35% |
| 2014 Q4 | 93.4 Million USD | -4.01% |
| 2014 Q3 | 97.3 Million USD | -14.65% |
| 2013 Q3 | 79 Million USD | -7.93% |
| 2013 FY | 114 Million USD | 32.87% |
| 2013 Q4 | 82.7 Million USD | 4.68% |
| 2013 Q2 | 85.8 Million USD | -9.53% |
| 2013 Q1 | 94.83 Million USD | -1.4% |
| 2012 Q2 | 92.95 Million USD | -2.4% |
| 2012 Q3 | 66.51 Million USD | -28.45% |
| 2012 Q4 | 96.18 Million USD | 44.61% |
| 2012 FY | 85.8 Million USD | -12.42% |
| 2012 Q1 | 95.23 Million USD | -2.79% |
| 2011 Q1 | 110.94 Million USD | -2.57% |
| 2011 Q2 | 105.33 Million USD | -5.05% |
| 2011 Q3 | 104.05 Million USD | -1.22% |
| 2011 Q4 | 97.96 Million USD | -5.85% |
| 2011 FY | 97.96 Million USD | -13.97% |
| 2010 FY | 113.87 Million USD | -13.29% |
| 2010 Q1 | 163.04 Million USD | 24.16% |
| 2010 Q2 | 125.29 Million USD | -23.15% |
| 2010 Q4 | 113.87 Million USD | -5.48% |
| 2010 Q3 | 120.47 Million USD | -3.84% |
| 2009 Q3 | 112.17 Million USD | -5.07% |
| 2009 Q1 | 137.1 Million USD | -4.94% |
| 2009 Q2 | 118.16 Million USD | -13.81% |
| 2009 Q4 | 131.31 Million USD | 17.06% |
| 2009 FY | 131.31 Million USD | -8.95% |
| 2008 FY | 144.22 Million USD | -39.55% |
| 2008 Q2 | 175.74 Million USD | -18.08% |
| 2008 Q3 | 167.58 Million USD | -4.65% |
| 2008 Q1 | 214.54 Million USD | -10.07% |
| 2008 Q4 | 144.22 Million USD | -13.94% |
| 2007 Q4 | 238.57 Million USD | 6.57% |
| 2007 FY | 238.57 Million USD | -10.27% |
| 2007 Q3 | 223.85 Million USD | -3.69% |
| 2007 Q2 | 232.43 Million USD | -2.81% |
| 2007 Q1 | 239.14 Million USD | -10.05% |
| 2006 Q3 | 277.65 Million USD | -3.87% |
| 2006 FY | 265.87 Million USD | -19.27% |
| 2006 Q1 | 302.94 Million USD | -8.01% |
| 2006 Q2 | 288.83 Million USD | -4.66% |
| 2006 Q4 | 265.87 Million USD | -4.24% |
| 2005 Q1 | 330.35 Million USD | -10.27% |
| 2005 Q4 | 329.33 Million USD | -20.65% |
| 2005 Q3 | 415.01 Million USD | -3.98% |
| 2005 Q2 | 432.21 Million USD | 30.83% |
| 2005 FY | 329.33 Million USD | -10.55% |
| 2004 Q4 | 368.17 Million USD | -2.62% |
| 2004 FY | 368.17 Million USD | -4.94% |
| 2004 Q1 | 382.6 Million USD | -1.21% |
| 2004 Q2 | 389.96 Million USD | 1.92% |
| 2004 Q3 | 378.09 Million USD | -3.04% |
| 2003 Q2 | 230.51 Million USD | 2.0% |
| 2003 Q4 | 387.3 Million USD | 26.15% |
| 2003 FY | 387.3 Million USD | 66.35% |
| 2003 Q1 | 225.98 Million USD | -2.93% |
| 2003 Q3 | 307.02 Million USD | 33.19% |
| 2002 FY | 232.81 Million USD | -24.97% |
| 2002 Q1 | 295.12 Million USD | -4.89% |
| 2002 Q2 | 221.41 Million USD | -24.98% |
| 2002 Q3 | 222.2 Million USD | 0.36% |
| 2002 Q4 | 232.81 Million USD | 4.77% |
| 2001 Q4 | 310.3 Million USD | 3.99% |
| 2001 Q3 | 298.39 Million USD | 35.77% |
| 2001 Q2 | 219.78 Million USD | 1.81% |
| 2001 Q1 | 215.86 Million USD | -3.84% |
| 2001 FY | 310.3 Million USD | 38.23% |
| 2000 FY | 224.48 Million USD | 4.61% |
| 2000 Q4 | 224.48 Million USD | 5.0% |
| 2000 Q1 | 204.07 Million USD | -4.9% |
| 2000 Q3 | 213.79 Million USD | -0.29% |
| 2000 Q2 | 214.41 Million USD | 5.07% |
| 1999 Q1 | 209.6 Million USD | -3.99% |
| 1999 Q3 | 203.1 Million USD | 0.45% |
| 1999 Q4 | 214.6 Million USD | 5.66% |
| 1999 FY | 214.6 Million USD | -1.69% |
| 1999 Q2 | 202.2 Million USD | -3.53% |
| 1998 FY | 218.3 Million USD | -3.36% |
| 1998 Q1 | 224.4 Million USD | -0.66% |
| 1998 Q2 | 215.8 Million USD | -3.83% |
| 1998 Q3 | 212.4 Million USD | -1.58% |
| 1998 Q4 | 218.3 Million USD | 2.78% |
| 1997 FY | 225.9 Million USD | 11.78% |
| 1997 Q4 | 225.9 Million USD | 1.03% |
| 1997 Q3 | 223.6 Million USD | 5.27% |
| 1997 Q2 | 212.4 Million USD | 2.51% |
| 1997 Q1 | 207.2 Million USD | 2.52% |
| 1996 Q1 | 184 Million USD | 33.33% |
| 1996 Q2 | 186.6 Million USD | 1.41% |
| 1996 Q3 | 191.1 Million USD | 2.41% |
| 1996 Q4 | 202.1 Million USD | 5.76% |
| 1996 FY | 202.1 Million USD | 46.45% |
| 1995 Q3 | 119.1 Million USD | 11.94% |
| 1995 Q4 | 138 Million USD | 15.87% |
| 1995 FY | 138 Million USD | 47.12% |
| 1995 Q1 | 96.7 Million USD | 3.09% |
| 1995 Q2 | 106.4 Million USD | 10.03% |
| 1994 Q4 | 93.8 Million USD | 13.7% |
| 1994 FY | 93.8 Million USD | 77.32% |
| 1994 Q1 | 73.5 Million USD | 38.94% |
| 1994 Q2 | 78.2 Million USD | 6.39% |
| 1994 Q3 | 82.5 Million USD | 5.5% |
| 1993 Q4 | 52.9 Million USD | 0.0% |
| 1993 Q1 | 47.1 Million USD | -0.84% |
| 1993 Q2 | 49.7 Million USD | 5.52% |
| 1993 FY | 52.9 Million USD | 11.37% |
| 1993 Q3 | 52.9 Million USD | 6.44% |
| 1992 Q1 | 40.7 Million USD | 53.01% |
| 1992 Q2 | 42.2 Million USD | 3.69% |
| 1992 Q3 | 47.4 Million USD | 12.32% |
| 1992 Q4 | 47.5 Million USD | 0.21% |
| 1992 FY | 47.5 Million USD | 78.57% |
| 1991 FY | 26.6 Million USD | 12.24% |
| 1991 Q2 | 22 Million USD | -0.9% |
| 1991 Q3 | 27 Million USD | 22.73% |
| 1991 Q4 | 26.6 Million USD | -1.48% |
| 1991 Q1 | 22.2 Million USD | -6.33% |
| 1990 Q3 | 26 Million USD | 7.88% |
| 1990 Q1 | 23.9 Million USD | -2.05% |
| 1990 Q2 | 24.1 Million USD | 0.84% |
| 1990 FY | 23.7 Million USD | -2.87% |
| 1990 Q4 | 23.7 Million USD | -8.85% |
| 1989 Q4 | 24.4 Million USD | 6.09% |
| 1989 Q3 | 23 Million USD | 8.49% |
| 1989 Q2 | 21.2 Million USD | 0.0% |
| 1989 FY | 24.4 Million USD | 16.75% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Absci Corporation | 234.48 Million USD | 60.837% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 86.11% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 97.602% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -14439.542% |
| Apollomics, Inc. | 55.38 Million USD | -65.797% |
| 180 Life Sciences Corp. | 5.25 Million USD | -1645.991% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 4.594% |
| Bicycle Therapeutics plc | 595.34 Million USD | 84.575% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 57.19% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -24.596% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -22.004% |
| Chimerix, Inc. | 212.77 Million USD | 56.842% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 95.881% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 29.571% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 74.146% |
| Fortress Biotech, Inc. | 167.52 Million USD | 45.185% |
| Fortress Biotech, Inc. | 167.52 Million USD | 45.185% |
| Gritstone bio, Inc. | 177.76 Million USD | 48.343% |
| Allakos Inc. | 243.61 Million USD | 62.305% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 29.304% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 27.029% |
| Cytokinetics, Incorporated | 824.31 Million USD | 88.86% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -5.601% |
| Innoviva, Inc. | 1.24 Billion USD | 92.615% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -864.573% |
| NLS Pharmaceutics AG | 1.84 Million USD | -4872.813% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 47.02% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -1294.211% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 65.801% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 34.807% |
| ImmuCell Corporation | 43.8 Million USD | -109.619% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 85.857% |
| Incyte Corporation | 6.78 Billion USD | 98.646% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 46.902% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -2877.64% |
| Mustang Bio, Inc. | 17.74 Million USD | -417.585% |
| MiMedx Group, Inc. | 239.04 Million USD | 61.585% |
| MEI Pharma, Inc. | 41.37 Million USD | -121.946% |
| MacroGenics, Inc. | 306.82 Million USD | 70.07% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -1150.211% |
| Mereo BioPharma Group plc | 66.49 Million USD | -38.092% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -436.159% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 46.269% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 93.826% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -61.387% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -303.099% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -2791.373% |
| NextCure, Inc. | 129.41 Million USD | 29.044% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 3.552% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -70.219% |
| Onconetix, Inc. | 88.82 Million USD | -3.387% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -150.02% |
| Opthea Limited | 188.79 Million USD | 51.359% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 36.241% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -8011.052% |
| PDS Biotechnology Corporation | 59.39 Million USD | -54.622% |
| Precigen, Inc. | 151.04 Million USD | 39.203% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -137.41% |
| Prime Medicine, Inc. | 193.85 Million USD | 52.629% |
| PureTech Health plc | 693.97 Million USD | 86.767% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 83.785% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.722% |
| Replimune Group, Inc. | 487.72 Million USD | 81.172% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -651.928% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 21.663% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -1676.312% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 95.603% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -385.265% |
| Sesen Bio, Inc. | 189.17 Million USD | 51.457% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 44.453% |
| Solid Biosciences Inc. | 164.93 Million USD | 44.325% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 85.017% |
| SciSparc Ltd. | 11.18 Million USD | -721.231% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 80.492% |
| TG Therapeutics, Inc. | 329.58 Million USD | 72.138% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 40.547% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -1035.667% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 88.36% |
| UroGen Pharma Ltd. | 178.31 Million USD | 48.5% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -12.541% |
| XOMA Corporation | 234.3 Million USD | 60.807% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 83.661% |
| AbCellera Biologics Inc. | 1.48 Billion USD | 93.829% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -81.135% |
| Cassava Sciences, Inc. | 151.66 Million USD | 39.451% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -224.804% |
| Precision BioSciences, Inc. | 159.78 Million USD | 42.528% |
| Dyadic International, Inc. | 8.21 Million USD | -1017.257% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -430.963% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -189.319% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 5.994% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 46.146% |
| IGM Biosciences, Inc. | 423.41 Million USD | 78.312% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 37.64% |
| Acelyrin, Inc. | 742.69 Million USD | 87.635% |
| Abeona Therapeutics Inc. | 64 Million USD | -43.48% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 88.977% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -533.02% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 78.614% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 45.396% |
| Senti Biosciences, Inc. | 119.48 Million USD | 23.145% |
| Mesoblast Limited | 669.15 Million USD | 86.277% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 84.051% |
| ChromaDex Corporation | 54.96 Million USD | -67.073% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -1463.793% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 62.007% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -1050.949% |
| Seer, Inc. | 436.26 Million USD | 78.951% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 73.054% |
| Novavax, Inc. | 1.85 Billion USD | 95.051% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -853.746% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 81.86% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -1607.512% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 87.756% |
| Celcuity Inc. | 191.21 Million USD | 51.977% |
| ContextLogic Inc. | 423 Million USD | 78.291% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 77.81% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 43.082% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.194% |
| Amarin Corporation plc | 831.68 Million USD | 88.959% |
| AnaptysBio, Inc. | 452.38 Million USD | 79.701% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -269.656% |
| Aptorum Group Limited | 20.64 Million USD | -344.911% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 69.897% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 88.005% |
| Ardelyx, Inc. | 297.57 Million USD | 69.141% |
| Celularity Inc. | 143.88 Million USD | 36.18% |
| Omeros Corporation | 378.26 Million USD | 75.724% |
| Humacyte, Inc. | 128.22 Million USD | 28.383% |
| Immunocore Holdings plc | 597 Million USD | 84.618% |
| IO Biotech, Inc. | 150.71 Million USD | 39.072% |
| GT Biopharma, Inc. | 14.1 Million USD | -550.861% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 63.797% |
| Summit Therapeutics Inc. | 202.94 Million USD | 54.752% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -1011.34% |
| Pulmatrix, Inc. | 33.95 Million USD | -170.422% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 92.941% |
| Evogene Ltd. | 51.1 Million USD | -79.703% |
| CorMedix Inc. | 82.05 Million USD | -11.906% |
| BioLineRx Ltd. | 63.92 Million USD | -43.653% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 25.736% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 5.055% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 95.175% |
| scPharmaceuticals Inc. | 94.47 Million USD | 2.804% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 64.365% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 85.225% |
| NLS Pharmaceutics AG | 1.84 Million USD | -4872.813% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -385.265% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 84.175% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 16.873% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -67.898% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 59.784% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 14.526% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -184.295% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -408.896% |
| Daré Bioscience, Inc. | 21.28 Million USD | -331.487% |
| bluebird bio, Inc. | 619.16 Million USD | 85.169% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 98.658% |
| DBV Technologies S.A. | 182.98 Million USD | 49.816% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 85.39% |
| Galecto, Inc. | 38.22 Million USD | -140.223% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -23.471% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 11.656% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 70.175% |
| GlycoMimetics, Inc. | 45.31 Million USD | -102.642% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 73.099% |
| ADMA Biologics, Inc. | 329.18 Million USD | 72.104% |
| Clene Inc. | 52.34 Million USD | -75.446% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 85.952% |
| Aptose Biosciences Inc. | 12.92 Million USD | -610.619% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -315.252% |
| Soligenix, Inc. | 9.79 Million USD | -837.297% |
| Century Therapeutics, Inc. | 360.69 Million USD | 74.541% |
| Kura Oncology, Inc. | 448.93 Million USD | 79.545% |
| Surrozen, Inc. | 46.08 Million USD | -99.284% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 66.257% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 17.204% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 55.238% |
| Autolus Therapeutics plc | 375.38 Million USD | 75.537% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 63.507% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -86.905% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 79.175% |
| GRI Bio, Inc. | 2.95 Million USD | -3006.563% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -765.894% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 75.86% |
| INmune Bio, Inc. | 57 Million USD | -61.102% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 58.729% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -9.398% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -251.612% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -685.904% |
| Jaguar Health, Inc. | 50.76 Million USD | -80.899% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -1234.119% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -22.072% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -169.945% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 44.515% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 85.415% |
| Verastem, Inc. | 149.71 Million USD | 38.665% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 82.07% |
| Histogen Inc. | 19.07 Million USD | -381.466% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -305.427% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 87.739% |
| Surrozen, Inc. | 46.08 Million USD | -99.284% |
| Organovo Holdings, Inc. | 6.34 Million USD | -1346.37% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -2031.309% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -977.912% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 74.7% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -407.505% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -628.132% |
| Kronos Bio, Inc. | 213.27 Million USD | 56.944% |
| Turnstone Biologics Corp. | 112.81 Million USD | 18.601% |
| Synaptogenix, Inc. | 31.11 Million USD | -195.144% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -653.693% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 80.428% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 83.245% |
| Exelixis, Inc. | 2.94 Billion USD | 96.879% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 74.809% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 88.357% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 3.722% |
| ESSA Pharma Inc. | 149.12 Million USD | 38.42% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -414.1% |
| Avid Bioservices, Inc. | 336.55 Million USD | 72.715% |
| Insmed Incorporated | 1.32 Billion USD | 93.095% |
| MediWound Ltd. | 66.45 Million USD | -38.175% |
| OmniAb, Inc. | 401.98 Million USD | 77.156% |
| Alector, Inc. | 621.82 Million USD | 85.232% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 74.392% |
| Zai Lab Limited | 1.03 Billion USD | 91.139% |
| AlloVir, Inc. | 190.79 Million USD | 51.87% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 80.807% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 63.944% |
| Aura Biosciences, Inc. | 255.07 Million USD | 63.999% |
| Immunic, Inc. | 54.29 Million USD | -69.119% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 65.506% |
| Veracyte, Inc. | 1.13 Billion USD | 91.929% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -676.721% |
| FibroGen, Inc. | 423.52 Million USD | 78.318% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -2514.005% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 80.541% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -1838.73% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -1591.323% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -942.93% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 82.253% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 97.892% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 60.99% |
| XBiotech Inc. | 227.24 Million USD | 59.59% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 3.722% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 75.183% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -1334.171% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 35.603% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 67.882% |
| Agenus Inc. | 313.91 Million USD | 70.747% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 28.184% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 75.961% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 93.841% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 74.83% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 82.237% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -393.462% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 75.606% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -757.008% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -314.561% |
| Lantern Pharma Inc. | 43.64 Million USD | -110.389% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 27.058% |
| Ainos, Inc. | 31.84 Million USD | -188.394% |
| Pluri Inc. | 39.52 Million USD | -132.322% |
| Prothena Corporation plc | 696.38 Million USD | 86.813% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 67.507% |
| Rallybio Corporation | 115.62 Million USD | 20.576% |
| Kodiak Sciences Inc. | 479.37 Million USD | 80.844% |
| Cue Biopharma, Inc. | 61.53 Million USD | -49.244% |
| MeiraGTx Holdings plc | 458.16 Million USD | 79.957% |
| Annexon, Inc. | 297.67 Million USD | 69.151% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 33.199% |
| Moderna, Inc. | 18.42 Billion USD | 99.502% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -193.771% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -34.0% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 91.248% |
| Immix Biopharma, Inc. | 19.92 Million USD | -360.875% |
| CalciMedica, Inc. | 12.18 Million USD | -653.632% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 69.768% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 70.476% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 66.601% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 83.755% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -238.282% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 29.464% |
| Nutriband Inc. | 7.51 Million USD | -1121.606% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -16.308% |
| Vor Biopharma Inc. | 209.82 Million USD | 56.236% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 98.729% |
| Alkermes plc | 2.13 Billion USD | 95.701% |
| ProKidney Corp. | 420.55 Million USD | 78.164% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -67.472% |
| Arcellx, Inc. | 825.13 Million USD | 88.871% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 83.193% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 77.189% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -225.638% |
| Atai Life Sciences N.V. | 293.47 Million USD | 68.71% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 43.707% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 27.93% |
| MediciNova, Inc. | 66.26 Million USD | -38.57% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -4.414% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -1957.877% |
| GeoVax Labs, Inc. | 9.28 Million USD | -889.204% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 84.389% |
| Biomea Fusion, Inc. | 199.92 Million USD | 54.068% |
| RenovoRx, Inc. | 1.46 Million USD | -6163.984% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 81.07% |
| Geron Corporation | 394.07 Million USD | 76.697% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -1155.366% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 72.983% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 44.373% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 82.553% |
| Royalty Pharma plc | 16.38 Billion USD | 99.439% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 66.931% |
| Imunon, Inc. | 21.91 Million USD | -318.969% |
| BioAtla, Inc. | 119.65 Million USD | 23.256% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 85.715% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 4.279% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 59.378% |
| Structure Therapeutics Inc. | 482.01 Million USD | 80.949% |
| 89bio, Inc. | 596.26 Million USD | 84.599% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 58.492% |
| aTyr Pharma, Inc. | 122.06 Million USD | 24.771% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 40.333% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 81.275% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -505.836% |
| Akari Therapeutics, Plc | 4.35 Million USD | -2008.611% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -438.993% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 94.702% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 59.975% |
| Liquidia Corporation | 120.43 Million USD | 23.749% |
| Entera Bio Ltd. | 11.76 Million USD | -680.535% |
| GH Research PLC | 226.3 Million USD | 59.421% |
| Vericel Corporation | 353.65 Million USD | 74.034% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 36.406% |
| Xencor, Inc. | 952.69 Million USD | 90.361% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -1079.762% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -251.612% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -1037.765% |
| Vaxcyte, Inc. | 1.4 Billion USD | 93.478% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 90.482% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 85.838% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -2877.64% |
| Portage Biotech Inc. | 7.77 Million USD | -1080.486% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -1957.877% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 66.842% |
| OncoCyte Corporation | 74.89 Million USD | -22.617% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -4416.419% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -1486.93% |
| Purple Biotech Ltd. | 44.3 Million USD | -107.282% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -77.955% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -102.773% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 72.402% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -169.091% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -140.286% |
| United Therapeutics Corporation | 7.16 Billion USD | 98.719% |
| HilleVax, Inc. | 344.43 Million USD | 73.339% |
| Silo Pharma, Inc. | 7.74 Million USD | -1085.494% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -1823.638% |
| Pharming Group N.V. | 462.85 Million USD | 80.16% |
| Tharimmune, Inc. | 10.94 Million USD | -738.906% |
| Genprex, Inc. | 10.67 Million USD | -760.59% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 77.123% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 81.493% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 47.141% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -3685.243% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -2104.568% |
| OKYO Pharma Limited | 1.54 Million USD | -5858.097% |
| Savara Inc. | 177.56 Million USD | 48.283% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -183.373% |
| Curis, Inc. | 77.28 Million USD | -18.825% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -43.599% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -374.059% |
| BeiGene, Ltd. | 5.8 Billion USD | 98.418% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 74.346% |
| Erasca, Inc. | 395.29 Million USD | 76.769% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -2024.038% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -2024.038% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -404.09% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -692.595% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 33.584% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 80.278% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 70.702% |
| Adicet Bio, Inc. | 207.29 Million USD | 55.701% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 88.195% |
| Aditxt, Inc. | 44.57 Million USD | -105.997% |
| Adagene Inc. | 115.72 Million USD | 20.651% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -1961.655% |
| Quantum-Si incorporated | 298.25 Million USD | 69.21% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -1091.186% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 73.859% |
| Compugen Ltd. | 121.33 Million USD | 24.316% |
| Generation Bio Co. | 374.75 Million USD | 75.496% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 63.941% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 42.088% |
| Invivyd, Inc. | 229.18 Million USD | 59.931% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 89.119% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -654.604% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 49.652% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -349.618% |
| 2seventy bio, Inc. | 565.42 Million USD | 83.759% |
| Instil Bio, Inc. | 325.63 Million USD | 71.799% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -56.348% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -1669.392% |
| GeoVax Labs, Inc. | 9.28 Million USD | -889.204% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 11.371% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 5.866% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 62.14% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 95.315% |
| Evaxion Biotech A/S | 12.88 Million USD | -612.489% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 63.568% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 87.8% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 59.342% |
| Cingulate Inc. | 3.49 Million USD | -2530.15% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -452.228% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -39.793% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 27.057% |
| Clearmind Medicine Inc. | 4.32 Million USD | -2023.537% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 42.529% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -972.704% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 75.079% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 85.664% |
| ImmunityBio, Inc. | 504.45 Million USD | 81.796% |
| Korro Bio, Inc. | 221.66 Million USD | 58.572% |
| Kineta, Inc. | 10.28 Million USD | -793.201% |
| BioVie Inc. | 25.2 Million USD | -264.284% |
| Codexis, Inc. | 136.56 Million USD | 32.755% |
| Celularity Inc. | 143.88 Million USD | 36.18% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 23.017% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 85.547% |
| Virax Biolabs Group Limited | 5.48 Million USD | -1574.517% |
| Cibus, Inc. | 544.41 Million USD | 83.132% |
| IN8bio, Inc. | 33.7 Million USD | -172.42% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 46.922% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -337.432% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 96.929% |
| Eyenovia, Inc. | 28.77 Million USD | -219.083% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 60.165% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -1171.179% |
| Elevation Oncology, Inc. | 89.09 Million USD | -3.074% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -50.724% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -12.486% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 80.135% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -198.634% |
| Moolec Science SA | 24.05 Million USD | -281.809% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 70.389% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 9.714% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 84.566% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 41.463% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -1212.83% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -663.512% |
| Humacyte, Inc. | 128.22 Million USD | 28.383% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 63.581% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -4863.784% |
| Genelux Corporation | 27.89 Million USD | -229.222% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -2.715% |
| Notable Labs, Ltd. | 19.54 Million USD | -369.935% |
| Immunovant, Inc. | 666.71 Million USD | 86.226% |
| Quantum-Si incorporated | 298.25 Million USD | 69.21% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -69.553% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 47.689% |
| Acasti Pharma Inc. | 73.3 Million USD | -25.28% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -1917.23% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 49.178% |
| PepGen Inc. | 143.05 Million USD | 35.807% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -378.655% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -1463.793% |
| Immuneering Corporation | 102.58 Million USD | 10.484% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -2031.309% |
| Belite Bio, Inc | 94.64 Million USD | 2.971% |
| XOMA Corporation | 234.3 Million USD | 60.807% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 60.62% |
| Bionomics Limited | 27.64 Million USD | -232.127% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 14.488% |
| uniQure N.V. | 831.68 Million USD | 88.959% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -1961.655% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 66.471% |
| Forte Biosciences, Inc. | 38.98 Million USD | -135.582% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -2154.54% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -149.328% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -1171.179% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -2514.005% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -676.838% |
| Altimmune, Inc. | 210.64 Million USD | 56.404% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 51.272% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 14.488% |
| Peak Bio, Inc. | 2.59 Million USD | -3436.8% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 46.712% |
| Benitec Biopharma Inc. | 52.21 Million USD | -75.886% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 73.138% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -164.084% |
| Zura Bio Limited | 100.84 Million USD | 8.938% |
| PolyPid Ltd. | 15.37 Million USD | -497.385% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -164.084% |
| argenx SE | 4.54 Billion USD | 97.978% |
| Immunome, Inc. | 148.54 Million USD | 38.178% |
| Verona Pharma plc | 308.12 Million USD | 70.197% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -5.601% |
| Shattuck Labs, Inc. | 159.56 Million USD | 42.449% |
| CervoMed Inc. | 9.97 Million USD | -820.83% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -706.375% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 48.814% |
| Moolec Science SA | 24.05 Million USD | -281.809% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -1401.108% |
| Design Therapeutics, Inc. | 289.64 Million USD | 68.295% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -26.097% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -1594.906% |
| Achilles Therapeutics plc | 161.45 Million USD | 43.124% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -972.704% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 53.924% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -20.493% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -58.557% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 82.56% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 56.333% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 93.709% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 85.798% |
| AEON Biopharma, Inc. | 6.84 Million USD | -1241.563% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 30.654% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 66.222% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -569.712% |
| NeurAxis, Inc. | 509.49 Thousand USD | -17923.623% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 88.232% |
| Lumos Pharma, Inc. | 40.63 Million USD | -125.971% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -30.389% |
| Palisade Bio, Inc. | 14.05 Million USD | -553.501% |
| Nutriband Inc. | 7.51 Million USD | -1121.606% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 65.606% |
| Neurogene Inc. | 222.57 Million USD | 58.742% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -1380.651% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 79.73% |
| Athira Pharma, Inc. | 160.24 Million USD | 42.694% |
| HCW Biologics Inc. | 28.51 Million USD | -222.056% |
| XOMA Corporation | 234.3 Million USD | 60.807% |
| Nektar Therapeutics | 398.03 Million USD | 76.929% |
| Arvinas, Inc. | 1.3 Billion USD | 92.961% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -438.993% |
| Merus N.V. | 458.49 Million USD | 79.971% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 55.066% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 49.041% |
| Rezolute, Inc. | 132.73 Million USD | 30.818% |
| Clene Inc. | 52.34 Million USD | -75.446% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -515.323% |
| BeyondSpring Inc. | 24.8 Million USD | -270.163% |
| Synlogic, Inc. | 75.55 Million USD | -21.549% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -674.153% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -880.671% |
| Peak Bio, Inc. | 2.59 Million USD | -3436.8% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 47.476% |
| Krystal Biotech, Inc. | 818.35 Million USD | 88.779% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 61.807% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 87.348% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -2467.11% |
| MannKind Corporation | 475.19 Million USD | 80.675% |
| Ikena Oncology, Inc. | 192.09 Million USD | 52.195% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -586.631% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 21.202% |
| Gossamer Bio, Inc. | 311.91 Million USD | 70.559% |
| CohBar, Inc. | 16.36 Million USD | -461.114% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -161.155% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -1155.366% |
| Legend Biotech Corporation | 1.84 Billion USD | 95.032% |
| Mural Oncology plc | 301.74 Million USD | 69.567% |
| Disc Medicine, Inc. | 367.99 Million USD | 75.046% |
| Champions Oncology, Inc. | 26.13 Million USD | -251.408% |
| REGENXBIO Inc. | 573.97 Million USD | 84.001% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -3290.957% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 40.519% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -660.46% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 72.994% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -53.296% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 38.089% |
| Cellectis S.A. | 334.27 Million USD | 72.528% |
| Longeveron Inc. | 12.17 Million USD | -654.065% |
| Repare Therapeutics Inc. | 253.9 Million USD | 63.832% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 97.187% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 54.279% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 95.603% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -5551.077% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 66.933% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 43.696% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 33.813% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -259.807% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.596% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 92.042% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -651.928% |
| Veru Inc. | 50.59 Million USD | -81.497% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -101.589% |
| Cingulate Inc. | 3.49 Million USD | -2530.15% |
| Passage Bio, Inc. | 150.54 Million USD | 39.002% |
| Context Therapeutics Inc. | 16.06 Million USD | -471.696% |
| Exicure, Inc. | 11.58 Million USD | -693.005% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 75.58% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 43.189% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -425.584% |
| Nuvalent, Inc. | 732.38 Million USD | 87.461% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -514.491% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -2.541% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -547.1% |
| OmniAb, Inc. | 401.98 Million USD | 77.156% |
| Anew Medical, Inc. | 19.45 Million USD | -371.989% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -243.591% |
| Lipocine Inc. | 23 Million USD | -299.242% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 34.317% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 69.947% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -9.398% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 24.445% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -1057.278% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 89.592% |
| Ocugen, Inc. | 64.54 Million USD | -42.268% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 26.265% |
| Q32 Bio Inc. | 306.11 Million USD | 70.002% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -2082.272% |
| Alumis Inc. Common Stock | 89.61 Million USD | -2.475% |
| Equillium, Inc. | 50.53 Million USD | -81.734% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -22.122% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -122.491% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -5299.056% |
| Dominari Holdings Inc. | 57.55 Million USD | -59.543% |
| Edesa Biotech, Inc. | 8.89 Million USD | -932.908% |
| vTv Therapeutics Inc. | 11.01 Million USD | -733.454% |
| Bio-Techne Corporation | 2.81 Billion USD | 96.736% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 90.201% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 88.683% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 66.928% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -120.205% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 86.245% |
| Nkarta, Inc. | 378.88 Million USD | 75.763% |
| BioCardia, Inc. | 2.98 Million USD | -2974.322% |
| Iterum Therapeutics plc | 26.25 Million USD | -249.709% |